The Future of Pharma: Technology's Opportunity to Improve Patient Care

Inside Digital Health | October 18, 2019

Tech innovation is impacting everyone, everywhere — including those in need of specialty medical care. Although there has been robust innovation across the healthcare industry as a whole, patient services and engagement tools, specifically in pharma, are lagging behind. The idea that doctors can simply write a prescription and send patients on the path to healing just isn’t the reality. People, especially those with a chronic condition or comorbidities necessitating multiple medications, require well-rounded, ongoing support to be successful in their medical treatment. Healthcare relationship management and patient engagement platforms can provide that level of support. More and more people are being diagnosed with chronic conditions. In fact, research shows that chronic diseases like heart disease will affect an estimated 164 million Americans by 2025. Additionally, the consumption and spend on prescription medication continues to climb, with 2018 data revealing that 5.8 billion prescriptions were dispensed at a total cost of $344 billion. However, only 30 to 50% of those medications were taken as prescribed. On top of this, physicians are stretched increasingly thin and not always able to dedicate the time required to help patients manage their increasingly complex medication regimens.

Spotlight

Contract development and manufacturing organisations (CDMOs) in the pharmaceutical world are on the up. They benefit from an increasing number of companies that outsource parts of their production to external service providers.

Spotlight

Contract development and manufacturing organisations (CDMOs) in the pharmaceutical world are on the up. They benefit from an increasing number of companies that outsource parts of their production to external service providers.

Related News

BUSINESS INSIGHTS

Biosero Collaborates with Araceli Biosciences for High-Content Analysis

Biosero, Inc. | February 02, 2022

Biosero, Inc., developer of laboratory automation solutions to orchestrate scientific discoveries, announced a collaboration with Araceli Biosciences that will allow scientists to integrate Araceli’s Endeavor™ high-speed imaging platform into automated workflows controlled by Biosero’s Green Button Go® software suite. The Endeavor platform offers extremely rapid imaging for high-content analysis projects. In just minutes, the instrument can provide subcellular resolution of every cell in plates with 96 wells, 384 wells, or 1,536 wells. Through this collaboration, scientists can now incorporate the Endeavor system into automated lab pipelines that are dynamically scheduled and orchestrated via Green Button Go software. “Endeavor is the first high-content system to offer simultaneous whole-well, high-resolution scanning at an order of magnitude higher throughput than current platforms. We are excited to team up with Biosero so we can unlock the full potential of the Endeavor platform for highly automated lab environments,” Jeffrey Harris, General Manager of Araceli Biosciences Biosero’s Green Button Go software allows scientists to automate workflows ranging from a single workstation to operations that span multiple labs. With a number of extensions, hundreds of available drivers, and an intuitive control interface with drag-and-drop capabilities, Green Button Go software is flexible, scalable, and easily customizable for a broad array of laboratory needs. “Biosero’s commitment to a hardware-agnostic approach means that we can work with leading technology developers to ensure that our customers get to choose the best tools for their needs,” said Tom Gilman, CEO of Biosero. “We are pleased to collaborate with Araceli for its game-changing technology to enable the next generation of automated high-content image analysis.” Biosero will be offering demonstrations of its Green Button Go software at the upcoming SLAS2022 International Conference and Exhibition taking place February 5-9 in Boston. Please visit us at booth 1413 to learn more. About Araceli Biosciences Araceli Biosciences is a data-driven technology company focused on disrupting the status quo of drug discovery by fusing innovative hardware platforms with proprietary AI-powered software. Araceli’s high content analysis platform Endeavor™ combines unmatched speed and resolution to address longstanding bottlenecks in pharmaceutical research and development. Providing ten times the throughput and double the resolution of previous platforms, Endeavor is revolutionizing drug discovery by delivering accelerated target identification and selection. With a strong industrial pedigree, Araceli is poised to usher in a new era of drug discovery. About Biosero, Inc. Biosero, now a member of the BICO group, develops science-centric software and laboratory automation solutions that enable researchers to orchestrate their discoveries at every stage. Our Green Button Go Scheduler software and integration services match laboratory automation to your science, creating a cohesive technology ecosystem that accelerates operations and increases productivity. Our Green Button Go Orchestrator applications provide an end-to-end laboratory management solution, directing workflows and operations in life science, biotechnology, pharmaceutical, and diagnostic research. We are passionate about partnering with organizations dedicated to enhancing life by addressing the world’s most significant needs.

Read More

BUSINESS INSIGHTS

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

Neurimmune | January 17, 2022

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTM™ technology platform. In the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from the collaboration. Ono will pay to Neurimmune an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales. "We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines. The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology." Jan Grimm, CSO of Neurimmune "We extremely appreciate Neurimmune's RTM™ technology platform as an excellent antibody creation technology through our drug discovery projects." said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. "Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases." About Neurimmune Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.

Read More

BUSINESS INSIGHTS

CATO SMS Acquires Nuventra in order to Expand its Drug Development Offering Into Clinical Pharmacology

Nuventra, CATO SMS | May 27, 2021

CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at significantly reducing development risk, costs, and timelines. CATO SMS now provides customers cutting-edge clinical pharmacology services such as strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), pharmacometrics (population PK), and biosimulation. Nuventra is well-known for its track record of transforming complex data into meaningful insights for over 650 biopharmaceutical companies across a wide range of therapeutic areas. Its team of scientific experts and senior consultants use the most advanced mathematical modeling tools in the industry to inform clinical design and predict trial outcomes. Nuventra's range of solutions include: • pharmacokinetics and pharmacodynamics (PK/PD), which describes the movement of drugs through the body from absorption to elimination (PK), as well as the body's biological response to drugs (PD) to determine optimal dosing paradigms, safety margins, and efficacy characteristics. • population pharmacokinetics (popPK and popPK/PD), which studies the variability in drug concentrations among individuals in a group of interest receiving clinically relevant doses of a drug. • clinical pharmacology strategic consulting, which includes overall and targeted clinical pharmacology strategy in support of marketing applications for drugs and biologics. • physiologically based pharmacokinetic (PBPK), which incorporates blood flow and tissue composition of organs to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs. • quantitative systems pharmacology (QSP), which models the interplay of the drug (dose, dosing regimen, etc.) with target biology, using computational systems to characterize the interaction between drugs, biological systems, and disease processes. • model-informed drug development (MIDD), which uses modeling techniques to improve the decision-making process in drug development, thereby leading to clinical trial efficiencies and, in some cases, replacing trials altogether. About Nuventra Nuventra is the pharmaceutical industry's preferred provider of clinical pharmacology, pharmacokinetics, and pharmacometrics consulting services. Nuventra provides pharmaceutical companies and contracts research organizations (CROs) with unique access to a hands-on team of industry-leading consultants with extensive experience in complex studies and analyses. By taking complex pharmacokinetic and pharmacometrics concepts and making them understandable and usable for common sense drug development, we embrace the notion that simplicity and clarity lead to smart decisions. About CATO SMS CATO SMS is a provider of specialized clinical research solutions formed in 2019 by the merger of Cato Research and SMS-oncology. CATO SMS, with over 30 years of professional experience focusing on the needs of small and emerging biopharmaceutical companies, effectively designs and executes studies from strategy to approval in complex indications and modalities throughout a wide range of therapeutic areas, with a proven center of excellence in oncology. The regulatory, therapeutic, and operational expertise of CATO SMS enables the company to meet and exceed expectations.

Read More